PurMinds Files Fiscal Q2 2026 Financials, Advances PCAOB Audit Toward OTCQB/QX Uplisting
核心洞察
PurMinds Enterprises filed its fiscal Q2 2026 financials on OTC Markets, reporting a net loss of $922,000 driven by $350,000 in R&D and licensing expenditures.
The company has launched a PCAOB audit expected to complete by early July 2026, a prerequisite for its planned uplisting to OTCQB or OTCQX market tiers.
Total private capital raised since the reverse takeover inception has exceeded $2.25 million, including $2.1 million under Regulation S closed in March 2026.
PurMinds Enterprises, Inc. (搜索) (OTC: PFSF), a clinical-stage precision medicine and neuroscience company, has formally submitted its financials for the fiscal second quarter ended March 31, 2026, on OTCMarkets.com, the company announced June 12. The filing marks a pivotal step in the company's transition from corporate restructuring toward an execution-focused growth phase, underpinned by a concurrent PCAOB audit aimed at securing an uplisting to the OTCQB or OTCQX market tiers.
The quarterly disclosure includes a Management's Discussion and Analysis of Financial Condition and Results of Operations (MD&A), published on pages 18–23 of the filed report, adhering to reporting standards typical of a reporting issuer despite the company not currently holding that designation.
Financial Performance and R&D Deployment
For the second quarter of fiscal 2026, PurMinds reported zero revenue and gross profit, unchanged from the prior-year period. Total operating expenses rose by $500,000 to $814,000, primarily attributable to a $350,000 charge for R&D and licensing fees compared to zero in the year-ago quarter. Other expense, net was $108,000, versus other income, net of $132,000 in Q2 fiscal 2025. The net loss widened to $922,000, or $(.00) per share, from $182,000, or $(.00) per share, in the same quarter of the prior fiscal year.
The $350,400 in strategic R&D deployments comprised a $250,000 licensing fee paid to SpectroChip Global Inc. (搜索) for photonic chip diagnostic platform rights under the Amended and Restated Strategic Partnership and Know-How Licensing Agreement dated February 8, 2026, and $100,400 allocated to a premier U.S. clinical research institution for collaborative neuromedicine programs.
Balance Sheet Optimization and Capital Inflows
The company achieved significant balance sheet cleanup during the period, including the formal cancellation and return of 1,500,000 legacy common shares, complete redemption and retirement of all outstanding Series A Preferred stock, cancellation of 1,000 Series B Preferred shares, and the full settlement and elimination of $300,000 in legacy promissory note liabilities.
Total private capital raised or formally committed since the inception of the reverse takeover has exceeded $2.25 million. This includes $2,101,781 closed under Regulation S and $40,000 under Regulation D during March 2026, with subsequent post-quarter cash receipts of $428,037 (Reg S) and $125,000 (Reg D) through May 20, 2026. Additionally, the company finalized a regulatory government audit of historical Canadian Scientific Research and Experimental Development (SR&ED) tax credits, securing a substantial portion of the claim as non-dilutive capital.
PCAOB Audit and Uplisting Strategy
The PCAOB audit pre-work formally commenced on May 6, 2026, with the hiring of an independent, third-party pre-audit accounting preparation firm. This firm is optimizing the company's financial records and preparing technical accounting memos to ensure audit readiness. Because the third-party team maintains a collaborative working relationship with the incoming principal PCAOB audit firm, the company anticipates a seamless data handoff and minimized auditing friction. The entire audit process is expected to be completed by the end of June or early July 2026.
Concurrently, PurMinds has initiated the formal corporate name change and ticker symbol change request process. Upon sign-off and publication of the PCAOB-audited financials, the company will coordinate with an institutional Market Maker to submit a Rule 15c2-11 application with FINRA to permanently remove lingering shell restrictions and re-establish a transparent public quote under its newly approved identity.
Strategic Vision
"Moving deeper into fiscal 2026, management is strictly execution-focused, moving past corporate restructuring and entering a high-growth public market phase," jointly stated Janet Qi, CEO, and Angelo Pizzuto, CFO of PurMinds. "Clearing our legacy obligations, bringing in strong private investment capital, executing this PCAOB audit, and driving our strategic commercialization initiatives are the foundational steps required to scale our corporate runway and achieve our targeted clinical milestones over the next 24 months."
PurMinds is building an integrated precision medicine ecosystem centered on advanced therapeutics for neurological disorders (搜索), decentralized diagnostics, and data-driven healthcare intelligence. Central to this strategy is the company's exclusive partnership with SpectroChip Global Inc. (搜索), which has developed a fingernail-sized photonic chip-based diagnostic system integrating spectrophotometry, chromatography, and lateral flow immunoassays. PurMinds serves as the exclusive global partner to develop and supply all rapid diagnostic kits used in the SpectroChip point-of-care testing platform.